These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16287792)

  • 1. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
    Clifford DB; Evans S; Yang Y; Acosta EP; Goodkin K; Tashima K; Simpson D; Dorfman D; Ribaudo H; Gulick RM
    Ann Intern Med; 2005 Nov; 143(10):714-21. PubMed ID: 16287792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries for patients. Neuropsychological side effects of efavirenz.
    Ann Intern Med; 2005 Nov; 143(10):I43. PubMed ID: 16287787
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
    Fumaz CR; Tuldrà A; Ferrer MJ; Paredes R; Bonjoch A; Jou T; Negredo E; Romeu J; Sirera G; Tural C; Clotet B
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):244-53. PubMed ID: 11873073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
    Pedrol E; Llibre JM; Tasias M; Currán A; Guardiola JM; Deig E; Guelar A; Martínez-Madrid O; Tikhomirova L; Ramírez R;
    HIV Med; 2015 Nov; 16(10):628-34. PubMed ID: 26238151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).
    Clifford DB; Evans S; Yang Y; Acosta EP; Ribaudo H; Gulick RM;
    HIV Clin Trials; 2009; 10(6):343-55. PubMed ID: 20133265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.
    Haas DW; Ribaudo HJ; Kim RB; Tierney C; Wilkinson GR; Gulick RM; Clifford DB; Hulgan T; Marzolini C; Acosta EP
    AIDS; 2004 Dec; 18(18):2391-400. PubMed ID: 15622315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
    Shikuma CM; Kohorn L; Paul R; Chow DC; Kallianpur KJ; Walker M; Souza S; Gangcuangco LMA; Nakamoto BK; Pien FD; Duerler T; Castro L; Nagamine L; Soll B
    HIV Clin Trials; 2018 Aug; 19(4):139-147. PubMed ID: 30451595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
    Marzolini C; Telenti A; Decosterd LA; Greub G; Biollaz J; Buclin T
    AIDS; 2001 Jan; 15(1):71-5. PubMed ID: 11192870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
    Fumaz CR; Muñoz-Moreno JA; Moltó J; Negredo E; Ferrer MJ; Sirera G; Pérez-Alvarez N; Gómez G; Burger D; Clotet B
    J Acquir Immune Defic Syndr; 2005 Apr; 38(5):560-5. PubMed ID: 15793366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.
    Moyle G; Fletcher C; Brown H; Mandalia S; Gazzard B
    HIV Med; 2006 May; 7(4):243-7. PubMed ID: 16630036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
    Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
    AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
    Grilo NM; Correia MJ; Sequeira C; Harjivan SG; Caixas U; Diogo LN; Marques MM; Monteiro EC; Antunes AM; Pereira SA
    Toxicol Lett; 2016 Oct; 260():28-35. PubMed ID: 27543169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients.
    Pérez-Molina JA
    HIV Clin Trials; 2002; 3(4):279-86. PubMed ID: 12187501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.
    Blanch J; Martínez E; Rousaud A; Blanco JL; García-Viejo MA; Peri JM; Mallolas J; De Lazzari E; De Pablo J; Gatell JM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):336-43. PubMed ID: 11468421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apropos of atypical melancholia with Sustiva (efavirenz)].
    Lang JP; Halleguen O; Picard A; Lang JM; Danion JM
    Encephale; 2001; 27(3):290-3. PubMed ID: 11488260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.